Literature DB >> 33074931

Molecular MR Contrast Agents.

Sergey Shuvaev1, Eman Akam, Peter Caravan.   

Abstract

Molecular magnetic resonance (MR) imaging utilizes molecular probes to provide added biochemical or cellular information to what can already be achieved with anatomical and functional MR imaging. This review provides an overview of molecular MR and focuses specifically on molecular MR contrast agents that provide contrast by shortening the T1 time. We describe the requirements for a successful molecular MR contrast agent and the challenges for clinical translation. The review highlights work from the last 5 years and places an emphasis on new contrast agents that have been validated in multiple preclinical models. Applications of molecular MR include imaging of inflammation, fibrosis, fibrogenesis, thromboembolic disease, and cancers. Molecular MR is positioned to move beyond detection of disease to the quantitative staging of disease and measurement of treatment response.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33074931      PMCID: PMC7719082          DOI: 10.1097/RLI.0000000000000731

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  5 in total

1.  Next-Generation Cancer Magnetic Resonance Imaging With Tumor-Targeted Alkylphosphocholine Metal Analogs.

Authors:  Ray R Zhang; Cynthia Choi; Christina L Brunnquell; Reinier Hernandez; Anatoly N Pinchuk; Joseph G Grudzinski; Paul A Clark; Alan B McMillan; Anjon Audhya; Justin Jeffrey; John S Kuo; Jamey P Weichert
Journal:  Invest Radiol       Date:  2022-06-22       Impact factor: 10.065

2.  Effects of Cations on HPTS Fluorescence and Quantification of Free Gadolinium Ions in Solution; Assessment of Intracellular Release of Gd3+ from Gd-Based MRI Contrast Agents.

Authors:  Angelo Scarciglia; Enza Di Gregorio; Silvio Aime; Giuseppe Ferrauto
Journal:  Molecules       Date:  2022-04-12       Impact factor: 4.927

3.  Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis.

Authors:  Philip A Waghorn; Diego S Ferreira; Derek J Erstad; Nicholas J Rotile; Ricard Masia; Chloe M Jones; Chuantao Tu; Mozhdeh Sojoodi; Yin-Ching I Chen; Franklin Schlerman; Jeremy Wellen; Robert V P Martinez; Kenneth K Tanabe; Bryan C Fuchs; Peter Caravan
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

4.  Evaluation of Physicochemical Properties, Pharmacokinetics, Biodistribution, Toxicity, and Contrast-Enhanced Cancer MRI of a Cancer-Targeting Contrast Agent, MT218.

Authors:  Yajuan Li; Songqi Gao; Hongfa Jiang; Nadia Ayat; Victoria Laney; Calin Nicolescu; Wenyu Sun; Michael F Tweedle; Zheng-Rong Lu
Journal:  Invest Radiol       Date:  2022-05-05       Impact factor: 10.065

5.  LDL mediated delivery of Paclitaxel and MRI imaging probes for personalized medicine applications.

Authors:  Sahar Rakhshan; Diego Alberti; Rachele Stefania; Valeria Bitonto; Simonetta Geninatti Crich
Journal:  J Nanobiotechnology       Date:  2021-07-13       Impact factor: 10.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.